Experience of Mycophenolate Mofetil in 10 Patients With Autoimmune-Related Interstitial Lung Disease Demonstrates Promising Effects

MMF is safe, well tolerated, and allows reduction or discontinuation of prednisone without worsening of symptoms or objective progression of disease. MMF is less toxic and its targeted antifibrotic properties make it a potentially more effective agent than CYC that may supplant it as a first-line agent or provide sensible post-CYC maintenance or synergistic strategy in the treatment of CTD-ILD.